Melphalan in Liver Tumors: A Study on Treatment Methods
Author Information
Author(s): A. Marinelli, J.H. van Dierendonck, G.M. van Brakel, H. Irth, P.J.K. Kuppen, U.R. Tjaden, C.J.H. van de Velde
Primary Institution: University Hospital, Leiden
Hypothesis
Isolated liver perfusion (ILP) allows for higher doses of melphalan compared to hepatic artery infusion (HAI) with less toxicity.
Conclusion
ILP with melphalan achieves higher drug concentrations in tumor tissue with negligible hepatic toxicity.
Supporting Evidence
- ILP allowed administration of a two times higher dose of melphalan compared to HAI.
- 90% of rats treated with ILP showed complete remissions.
- ILP resulted in four times higher concentrations of melphalan in tumor tissue compared to HAI.
Takeaway
This study shows that giving a special cancer drug called melphalan directly to the liver can work better and be safer than giving it through the bloodstream.
Methodology
The study compared the effects of melphalan administered via isolated liver perfusion and hepatic artery infusion in male WAG/Ola rats with liver tumors.
Limitations
The study was conducted on rats, which may not fully represent human responses.
Participant Demographics
Male WAG/Ola rats weighing 260 to 360 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website